Taysha Gene Therapies (NASDAQ:TSHA) Rating Reiterated by Cantor Fitzgerald
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a note issued to investors on Thursday, Benzinga reports. They currently have a $7.00 target price on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 136.49% from the company’s previous […]
More Stories
US Sanctions 35 Individuals, Entities to Dismantle Iran’s Shadow Banking
By Kimberly Hayek The U.S. Treasury Department on April 28 imposed sanctions on 35 individuals and entities accused of running...
Iran War Pushes Gulf Allies to Request Dollar Help—What to Know
By Andrew Moran Treasury Secretary Scott Bessent confirmed last week that several U.S. allies in the Gulf region and Asia...
DC Shooting Suspect Charged With Attempting to Assassinate Trump
By Stacy Robinson and Jackson Richman WASHINGTON—The Department of Justice has charged Cole Allen, the suspect in the White House...
United Arab Emirates to Leave OPEC Next Month
By Andrew Moran The United Arab Emirates said it is leaving OPEC and the broader alliance. “This decision follows a...
Improper US Government Payments Rose to $186 Billion in 2025: Watchdog
By Sylvia Xu Federal government agencies reported a total estimate of about $186 billion in improper payments in fiscal year...
US Homebuilders Lean on Incentives to Unload Homes in Challenging Market
By Panos Mourdoukoutas Homebuilder earnings reports released in recent days point to a challenging environment for the industry, as companies...